Introducing a novel approach to targeted protein degradation, biological PROTACs (bioPROTACs) represent a promising alternative to traditional methods such as PROTACs. By engineering intracellular proteins fused with target-binding domains and E3 ubiquitin ligases, bioPROTACs offer enhanced specificity and efficacy in degrading challenging targets like proliferating cell nuclear antigen (PCNA). This innovative technology not only provides powerful tools for understanding degradation mechanisms and target biology but also holds significant potential for therapeutic applications, offering new avenues for treating diseases by precisely modulating protein levels and functions.

bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA)Exquisitely Specific anti-KRAS Biodegraders Inform on the Cellular Prevalence of Nucleotide-Loaded States

Advantages of Choosing LifeSensors for your PROTAC Drug Discovery

  • Study PROTAC mediated Ubiquitination and Degradation simultaneously
  • Complete suite of validation studies to establish binding, ternary complex formation, and cellular degradation
  • Experience with novel E3 ligases – ~30 E3 ligases amenable to PROTAC discovery
  • Proteomics to characterize protein degradation – establish selectivity